Press Releases

Report from the Annual General Meeting of Immunicum AB (publ) on April 26, 2017

GOTHENBURG, Sweden, April 26, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the resolutions adopted at the Annual General Meeting held in Gothenburg.

The following res (...)

Read more

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in May

Press release

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in May

GOTHENBURG, Sweden, April 24, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced  (...)

Read more

Immunicum AB (publ) Announces Annual General Meeting of Shareholders

GOTHENBURG, Sweden, March 27, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, has resolved to issue a notice of summons to the annual general meeting, which will be held on Wednesday, Ap (...)

Read more

Immunicum's uplisting to Nasdaq Stockholm postponed

GOTHENBURG, Sweden, March 24, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, announced today that Nasdaq Stockholm's listing committee has postponed the decision on Immunicum's applicat (...)

Read more

Immunicum AB Publishes the Annual Report for 2016

GOTHENBURG, Sweden, March 17, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that its Annual Report for July-December 2016 is now available in Swedish to read and to dow (...)

Read more

Immunicum AB Announces Enrollment of First Patient in Phase I/II GIST Trial Following Study Protocol Amendment

GOTHENBURG, Sweden, March 7, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that a new patient has been enrolled in the Phase I/II Gastrointestinal Stromal Tumor (GIST)  (...)

Read more

Immunicum AB Appoints Sijme Zeilemaker as Senior Director Business Development

GOTHENBURG, Sweden, March 2, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the appointment of Sijme Zeilemaker as Senior Director Business Development. Mr. Zeilemaker j (...)

Read more

Immunicum AB Announces Presentations and Participations at Upcoming Conferences in March

GOTHENBURG, Sweden, March 1, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, will participate and hold presentations at severa (...)

Read more

Immunicum AB: Year-End Report 2016 (July 2016 - December 2016)

GOTHENBURG, Sweden, February 17, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced financial results for the year ended December 31, 2016 and provided a corporate update an (...)

Read more

Immunicum AB announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma

GOTHENBURG, Sweden, February 14, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) in F (...)

Read more

Immunicum AB Appoints Karin Hoogendoorn as Head of CMC

GOTHENBURG, Sweden, February 13, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the appointment of Karin Hoogendoorn as Head of Chemistry, Manufacturing and Controls (CM (...)

Read more

Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast

GOTHENBURG, Sweden, February 9, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that on February 17, 2017 the Company will release its financial results for the fourth qu (...)

Read more

Immunicum AB CEO to present at BIO CEO & Investor Conference

GOTHENBURG, Sweden, February 3, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, will present at the BIO CEO & Investor Con (...)

Read more

Immunicum AB announces FDA clearance of its Investigational New Drug application for INTUVAX in metastatic renal cell carcinoma

GOTHENBURG, Sweden, December 13, 2016 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company developing sophisticated, safe and efficacious therapeutic cancer treatments, inducing powerful and long lasting immune responses, today announced that the United States Food and Dru (...)

Read more

Immunicum CEO purchases shares in the Company

Press release

GOTHENBURG, Sweden, December 2, 2016 - Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company striving to develop sophisticated, safe and efficacious therapeutic cancer treatments inducing powerful and long lasting immune responses, today announced that CEO, Ca (...)

Read more

Immunicum's nomination committee for the Annual General Meeting 2017 appointed

In accordance with the resolution by the Annual General Meeting of Immunicum on 26 October 2016, the Chairman of the Board of Directors has convened a Nomination Committee for the Annual General Meeting 2017. The four largest shareholders who wish to participate in the nomination committe are entitl (...)

Read more

Immunicum: Quarterly report July 2016 - September 2016

Continued improvement in survival data both in kidney cancer and liver cancer. Enrolment process for the ongoing MERECA phase II study now implemented across Europe.


First quarter in brief

Business highlights

> Two patent applications that relate to the Company's CD70-technology in important fu (...)

Read more

Immunicum AB presented poster at SITC conference on INTUVAX HCC I/II clinical study - announces last patient included in study extension

GOTHENBURG, Sweden, November 14, 2016 - Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company striving to develop sophisticated, safe and efficacious therapeutic cancer treatments inducing powerful and long lasting immune responses, today announced updated immunological and  (...)

Read more

Immunicum AB: Report from the Annual General Meeting of Immunicum AB (publ) on October 26, 2016

Gothenburg October 26, 2016 - At the Annual General Meeting ("AGM") of Immunicum AB (publ), reg.no 556629-1786, the following resolutions were mainly adopted. For more detailed information on the content of the resolutions, please see the press release published on September 26, 2016 and the complet (...)

Read more

Immunicum AB Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development

Gothenburg, Sweden, September 27, 2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced the appointment of Carlos de Sousa as Immunicum's Chief Execu (...)

Read more

Immunicum to present at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting November 11 - 13

Gothenburg, Sweden, September 19, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that it will present data from its INTUVAX - HCC I/II clinical (...)

Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

Gothenburg, Sweden, September 16 2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced continued data improvement from the follow-up phase of a phase (...)

Read more

Immunicum announces that a patent application in the USA regarding the Company's CD70-technology will be granted

Gothenburg, Sweden, September 14, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the United States Patent and Trademark Office (USPTO) int (...)

Read more

Immunicum: Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm proposed as new Board members

Gothenburg, Sweden, August 25, 2016 - The nomination committee of Immunicum AB (publ) proposes that Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm be elected as new Board members at the Annual General Meeting on October 26, 2016.

"Immunicum is now entering a new exciting phase, w (...)

Read more

Immunicum AB announces change of the financial calendar

With respect to the planned change of market place of trading from Nasdaq First North Premier to Nasdaq OMX main list, Immunicum AB's Board of Directors has resolved to change the dates for publishing the Company's Year-end report 2015/2016, Annual report 2015/2016 and the Annual General Meeting 201 (...)

Read more

Immunicum announces that a patent application in China regarding the Company's CD70-technology will be granted

Gothenburg, Sweden, July 26, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Chinese Patent Office (SIPO) intends to grant a patent rel (...)

Read more

Immunicum submits IND application to the Food and Drug Administration (FDA) for approval to treat kidney cancer patients in the United States in its ongoing phase II-trial

Gothenburg, Sweden, July 22, 2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Company has submitted an Investigational New Drug (IND) a (...)

Read more

Immunicum AB Announces Appointment of Chief Medical Officer, Peter Suenaert, M.D., Ph.D.

Gothenburg, Sweden, July 22, 2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, announced today that Peter Suenaert, M.D., Ph.D., has accepted the offer to take t (...)

Read more

Immunicum Announces Preliminary Plans to Initiate Clinical Trials with INTUVAX in Melanoma in both Sweden and the U.S.

Gothenburg, Sweden, June 23, 2016 - Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced preliminary plans to conduct two separate studies with INTUVAX for the treatment of advanced m (...)

Read more

Immunicum raises approximately SEK 128 million in oversubscribed rights issue - exercises over-allotment option

Gothenburg, Sweden, June 21, 2016. Immunicum's rights issue of approximately SEK 111 million, which ended on June 14, 2016, was oversubscribed. In view of the strong demand from both new and existing shareholders the over-allotment option has been exercises in part, amounting to approximately SEK 17 (...)

Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

Gothenburg, Sweden, June 13 2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced continued data improvement from the follow-up phase of a phase I/II (...)

Read more

Information from the Extraordinary General Meeting of IMMUNICUM Aktiebolag (publ)

At the Extraordinary General Meeting (the "EGM") in IMMUNICUM Aktiebolag (publ) on 18 May 2016, the shareholders adopted the resolutions summarized below:

The EGM resolved to carry out a rights issue of shares with preferential rights for shareholders in accordance with the proposal of the Board of  (...)

Read more

Immunicum Engages US Based Accelovance and the Midwest Melanoma Partnership (MMP) to Evaluate INTUVAX and to Advance the Clinical Studies Pipeline into the US

Gothenburg, Sweden, May 17, 2016 - Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced the establishment of a clinical development services agreement with Accelovance to advance the  (...)

Read more

Immunicum applies for listing on the Nasdaq Stockholm main market

Gothenburg, Sweden, May 2, 2016. Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Company has applied for listing of its shares on the Nasdaq Stockholm main market. As pa (...)

Read more

Immunicum announces fully underwritten rights issue of about SEK 111 million to extend phase II-trial with new clinics in the US and to initiate clinical trials in melanoma in the US and in Sweden

The Board of Directors of Immunicum AB (publ) ("Immunicum") proposes the Extraordinary General Meeting ("EGM") resolve on a rights issue of approximately SEK 111 million and an overallotment option of approximately SEK 20 million. The rights issue is covered in its entirety by subscription and under (...)

Read more

Immunicum announces that a patent application in China regarding the cancer immune primer INTUVAX will be granted

Gothenburg, Sweden, April 22, 2016. Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Chinese Patent Office (SIPO) intends to grant a patent relating to the Company's canc (...)

Read more

Immunicum announces phase I/II data showing tumor specific immune responses that directly correlate with prolonged survival rates for the majority of liver cancer patients treated with INTUVAX

Gothenburg, Sweden, April 18, 2016 - Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced new immunological phase I/II data showing that the majority of liver cancer patients that rec (...)

Read more

Immunicum AB Announces Hiring New Investor Relations Firm

Gothenburg, Sweden, March 14, 2016 - Immunicum AB (publ), striving to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Company has engaged The Blueshirt Group to assist Immunicum in developing its commun (...)

Read more

Immunicum announces an update on its Phase I/II study in liver cancer and reports that the first patient in the extended part of the study has been treated with the cancer immune primer INTUVAX

Gothenburg, Sweden, March 10, 2016 - Immunicum AB (publ), striving to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced an update on the Company's Phase I/II trial in liver cancer. The Company also announced that  (...)

Read more

Immunicum announces new member of the Scientific Advisory Board, Anders Öhlén, further expanding the industrial experience and expertise in clinical development

Gothenburg, Sweden, March 3, 2016 - Immunicum AB (publ), developer of sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that Anders Öhlén was appointed as the newest member of the Company's Scientific Advisory Board. (...)

Read more

Immunicum's adenovirus technology gets green light for clinical study

Gothenburg, Sweden, 2016-02-01 08:45 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) today announced that the University Hospital in Uppsala has received clearance to initiate a clinical study in patients with neuroendocrine tumors with the Company's genetically modified adenovirus vector.

The s (...)

Read more

Immunicum gives a status update from the ongoing phase II study (MERECA) in metastatic kidney cancer and reports significantly simplified vaccine cell handling

Gothenburg, Sweden, 2016-01-29 08:28 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) today reports a significantly improved vaccine cell handling and gives a status update from the ongoing phase II study (MERECA) with the cancer immune primer INTUVAX in patients with metastatic renal cell carcino (...)

Read more

Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line treatments

Gothenburg, Sweden, 2015-12-16 08:57 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) announced today that the Swedish Medical Products Agency and the Ethics Committee has approved that the phase I/II-study in liver cancer may be extended by up to six patients who will receive INTUVAX in combinati (...)

Read more

Immunicum announces that the Company has received approval to start a phase I/II study in patients with gastrointestinal stromal tumor

Gothenburg, Sweden, 2015-12-16 08:30 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) announces that it has received clearance from the Medical Products Agency and the Ethics Committee to start its fourth clinical study with the cancer immune primer INTUVAX. The study will be conducted on 12 patie (...)

Read more

Immunicum reports updated data from the INTUVAX phase I/II study in liver cancer and announces plan for the continuation of the study

Gothenburg, Sweden, 2015-11-25 12:09 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) today reported an update on the safety and survival data from the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. Currently, ten patients have received at least one dose of INTUVAX an (...)

Read more

Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Japan

Gothenburg, Sweden, 2015-11-20 10:05 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) reported today that the Japan Patent Office (JPO), has announced that it intends to grant a patent relating to the Company's cancer immune primer, INTUVAX.

- We are pleased with the positive news from the Japan P (...)

Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

Gothenburg, 2015-11-17 14:00 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) today announced continued data improvement from the follow-up phase of a phase I/II-trial in eleven patients with metastatic kidney cancer that started in February 2012. Six patients are still alive and the data show an  (...)

Read more

Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Europe

Gothenburg, Sweden, 2015-11-09 15:36 CET (GLOBE NEWSWIRE) --  

Immunicum AB (publ) reported today that the European Patent Office (EPO), has announced that it intends to grant a patent relating to the Company's cancer immune primer, INTUVAX.

- We are pleased with the positive news from the Euro (...)

Read more

Immunicum prepares for listing on NASDAQ Stockholm's main market in 2016

Gothenburg, Sweden, 2015-10-30 13:41 CET (GLOBE NEWSWIRE) --  

The Board of Immunicum has decided to explore the possibility of carrying out a listing of its shares on NASDAQ Stockholm's main market in 2016. Immunicum's shares are traded since April 22, 2013 on NASDAQ First North under the tick (...)

Read more

IMMUNICUM AB: YEAR-END REPORT 2014/2015 (JULY-JUNE)

Gothenburg, Sweden, 2015-09-18 14:00 CEST (GLOBE NEWSWIRE) --  

FINANCIAL YEAR 2014/2015 COMPARED TO 2013/2014

Profit/loss after financial items was -35.6 MSEK (-16.2)

The number of shares at the end of the period was 20 030 000 (20 030 000)

Profit/loss per share before and after dilu (...)

Read more

Immunicum in collaboration with Karolinska Institute submits an application for starting a clinical study with INTUVAX® in GIST

Gothenburg, Sweden, 2015-09-17 15:34 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that it, together with Karolinska Institute and Karolinska University Hospital, has filed an application with the Swedish Medical Products Agency to start a phase I/II study with the Company's therapeut (...)

Read more

Immunicum provides Ad5PTDf35 adenovirus technology to Rutgers Cancer Institute

Gothenburg, Sweden, 2015-09-07 09:00 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) has signed a researchn agreement with Rutgers Cancer Institute of New Jersey, in USA to supply the institution with the Company's adenovirus (Ad5PTDf35) technology.

Immunicum's patented adenovirus vector, which is curr (...)

Read more

Immunicum updates safety and survival data in phase I/II liver cancer study with INTUVAX

Gothenburg, Sweden, 2015-08-24 12:50 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today released an updated report on safety and survival data from the ongoing phase I/II study with INTUVAX for patients with primary liver cancer. Of a total of seven fully treated patients, four showed a prolonged su (...)

Read more

Magnus Persson proposed new Board member of Immunicum

Gothenburg, Sweden, 2015-08-13 15:15 CEST (GLOBE NEWSWIRE) -- The Nomination Committee of Immunicum AB (publ) proposes that Magnus Persson be elected as a new member of the Board at the Annual General Meeting (December 3, 2015).

Dr. Magnus Persson has fifteen years of experience in venture capital a (...)

Read more

Immunicum strengthens the clinical organization

Gothenburg, Sweden, 2015-08-05 09:00 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) strengthens its organization with the recruitment of Linda Barkemo as Director Clinical Operations.

Linda Barkemo has more than 10 years of experience from leading positions in clinical project development in the pharm (...)

Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

Gothenburg, Sweden, 2015-08-04 09:00 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced continued improvement in survival data from the follow-up phase of a clinical phase I/II trial in patients with metastatic renal cell cancer. Seven of eleven evaluable patients are still alive.

Immunicu (...)

Read more

Immunicum hires Lise-Lotte Hallbäck as new CFO

Gothenburg, Sweden, 2015-07-13 08:30 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) strengthens its organization with the recruitment of Lise-Lotte Hallbäck as CFO.

Lise-Lotte Hallbäck will assume the position on October 1st and most recently served as Head of the Gothenburg office at Visma Services A (...)

Read more

Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer

Gothenburg, Sweden, 2015-05-05 09:01 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the first patient has been included in the international phase II study with the therapeutic cancer vaccine INTUVAX for the treatment of patients with metastatic kidney cancer.

INTUVAX is a therap (...)

Read more

Immunicum clarifies statement on liver cancer study

Gothenburg, Sweden, 2015-04-28 16:04 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced a clarification in response to several questions on Immunicum's update on the HCC phase I/II study from April 23 concerning the number of patients who are still alive in the study. A total of 4 of the 9 (...)

Read more

Immunicum updates safety and survival data in liver cancer study with INTUVAX

Gothenburg, Sweden, 2015-04-23 13:26 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today reported updated safety and survival data in the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. Six out of eight included liver cancer patients were able to receive all three vaccine (...)

Read more

Immunicum: Management sells a small amount of their shares

Gothenburg, Sweden, 2015-04-17 17:35 CEST (GLOBE NEWSWIRE) -- CEO Jamal El-Mosleh and Chief Scientific Officer Alex Karlsson-Parra in Immunicum AB (publ) have for personal financial reasons sold a small amount of their shares in the Company. They still maintain more than 85% of their previous total  (...)

Read more

Immunicum supplies NCI research with technology for CRISPR/Cas9 system

Gothenburg, Sweden, 2015-03-27 12:18 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the Company will deliver a genetically modified adenovirus vector to the American Frederick National Laboratory for Cancer Research (FNLCR), that on behalf of the National Cancer Institute (NCI), co (...)

Read more

Immunicum's Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology

Gothenburg, Sweden, 2015-03-13 09:06 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the Company's Chief Scientific Officer, Dr. Alex Karlsson-Parra, has presented the technology behind the cancer vaccine INTUVAX at the conference "Symposium on Breakthroughs in Clinical & Transl (...)

Read more

Immunicum receives approval to start phase II study with the therapeutic cancer vaccine INTUVAX

Gothenburg, Sweden, 2015-02-17 17:12 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the Swedish Medical Products Agency has granted the Company's application to commence a phase II clinical trial in patients with renal cell carcinoma with the therapeutic cancer vaccine INTUVAX in S (...)

Read more

Patent for the production of Immunicum's therapeutic cancer vaccines to be granted in Europe

Gothenburg, Sweden, 2015-01-27 15:10 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the Company's therapeutic cancer vaccines.

 

- We are pleased with the posi (...)

Read more

Immunicum: Patent application related to Immunicum's therapeutic cancer vaccine SUBCUVAX to be granted in the US

Gothenburg, Sweden, 2014-12-19 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the US Patent and Trademark Office has declared its intention to approve the Company's patent application for a genetically modified adenovirus vector. The vector is, among other things, intended to (...)

Read more

Immunicum: The patent application relating to activation of Immunicum's COMBIG-cells for therapeutic cancer vaccination will be granted in the US

Gothenburg, Sweden, 2014-12-15 09:04 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the United States Patent and Trademark Office (USPTO) has submitted a "Notice of Allowance" regarding patent application 13/522,741 and thereby intends to approve Immunicum's patent to protect  (...)

Read more

Immunicum presents safety and survival data from a clinical phase I/II study with INTUVAX in patients with liver cancer

Gothenburg, Sweden, 2014-12-03 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today published an interim report on the safety and survival data from the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. Based on the results achieved so far, an independent safety co (...)

Read more

Immunicum reports continued promising survival data for INTUVAX-treated renal cancer patients

Gothenburg, Sweden, 2014-12-03 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced continued promising data from a phase I/II trial in patients with metastatic renal cell carcinoma. The median survival in the subgroup of five individuals who were initially classified as high-risk  (...)

Read more

Immunicum's CSO Alex Karlsson-Parra awarded the Athena Prize

Gothenburg, Sweden, 2014-11-26 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the company's founder and Chief Scientific Officer, Alex Karlsson-Parra, has been awarded the Athena Prize for his creative and innovative development of therapeutic cancer vaccines, which cons (...)

Read more

Immunicum acquires patent for oncolytic therapy and further development of SUBCUVAX

Gothenburg, Sweden, 2014-10-27 14:15 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that it has acquired the patent rights to a genetically modified adenovirus vector. The vector is primarily intended to be used for efficient loading of vaccine cells by a variety of tumor antigens  (...)

Read more

Immunicum presents updated survival data for INTUVAX-treated renal cancer patients

Gothenburg, Sweden, 2014-09-12 12:58 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that updated survival data from a completed Phase I/II study of INTUVAX will be presented on September 15 at the 3rd Annual Cancer Vaccines Conference in London. In this study, the therapeutic canc (...)

Read more

Immunicum's rights issue oversubscribed

Gothenburg, Sweden, 2014-06-03 08:45 CEST (GLOBE NEWSWIRE) -- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this  (...)

Read more

Immunicum announces INTUVAX phase I/II data at ASCO 2014

Gothenburg, Sweden, 2014-06-02 08:30 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), a biopharmaceutical company developing therapeutic cancer vaccines, today announced that phase I/II data has been presented during a general poster session at the American Society of Clinical Oncology's (ASCO) 20 (...)

Read more

Immunicum publishes supplement to prospectus for rights issue

Gothenburg, Sweden, 2014-05-26 12:24 CEST (GLOBE NEWSWIRE) -- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this  (...)

Read more

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell ...

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell carcinoma

Gothenburg, Sweden, 2014-05-21 13:44 CEST (GLOBE NEWSWIRE) -- In addition to continued c (...)

Read more

Immunicum - INTUVAX abstract at ASCO 2014

Gothenburg, Sweden, 2014-05-15 07:43 CEST (GLOBE NEWSWIRE) -- Immunicum announces that the abstract on INTUVAX clinical data has been released for ASCO 2014

- Being accepted to present at the most prestigious cancer conference in the world gives us a great opportunity to showcase Immunicum's te (...)

Read more

Date for Immunicum's interim report for the period July 2013 - March 2014 changed

Göteborg, Sweden, 2014-04-15 10:33 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) ("Immunicum") has decided to change the date of publication of its interim report for the period 1 July 2013 - 31 March 2014. The new date of publication is 7 May 2014. The previously announced date of publication was 20 (...)

Read more

Immunicum has completed a private placement and resolved on a fully underwritten rights issue

Göteborg, Sweden, 2014-04-02 08:50 CEST (GLOBE NEWSWIRE) -- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this pr (...)

Read more

Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data

Göteborg, Sweden, 2014-03-31 08:56 CEST (GLOBE NEWSWIRE) -- Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. No vaccin (...)

Read more

Immunicum's abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago

Göteborg, Sweden, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) -- Immunicum today announced that an abstract has been approved to for presentation at the American Society of Clinical Oncology's's, ASCO, annual convention held in Chicago May 30-June 3, 2014.

The abstract, with title "Intratumoral  (...)

Read more

Immunicum reports promising preclinical results for its CD70 technology in adoptive immunotherapy

Gothenburg, Sweden, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) -- Promising data for Immunicum's CD70-technology for adoptive immunotherapy are today being published in a scientific journal. The results indicate a robust method to expand tumor-specific T-cells with improved quality in comparison wit (...)

Read more

Immunicum: Interim Report July - December 2013

Gothenburg, Sweden, 2014-02-18 08:59 CET (GLOBE NEWSWIRE) -- Second half of 2013 compared with the same period in 2012

Profit/Loss

The net loss for the period July 1 - December 31, 2013 amounted to - 5 583 KSEK, compared to - 2 177 KSEK for the same period in 2012. Earnings per share amounted t (...)

Read more

Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer

Gothenburg, Sweden, 2013-12-05 09:00 CET (GLOBE NEWSWIRE) -- Immunicum® AB (publ), a Swedish listed company on NASDAQ OMX First North, developing therapeutic cancer vaccines, today announces positive survival data from a clinical phase I/II-study with the therapeutic cancer vaccine INTUVAX ® fo (...)

Read more

Immunicum : Sven Andréasson new Board member

Gothenburg, Sweden, 2013-12-03 14:15 CET (GLOBE NEWSWIRE) -- Sven Andréasson has been appointed member of the Board of cancer vaccine company Immunicum AB (publ) in Gothenburg, Sweden. He succeeds Bengt Andersson, who will instead be included in the Company's Scientific Advisory Board.

Sven And (...)

Read more

Immunicum's patent application regarding the Company's core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.

Gothenburg, Sweden, 2013-10-25 08:53 CEST (GLOBE NEWSWIRE) -- The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819 and thus intends to approve Immunicum's patent application to protect the Company's core-technology in th (...)

Read more

Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer

Gothenburg, Sweden, 2013-10-23 12:27 CEST (GLOBE NEWSWIRE) -- The first patient in Immunicum's clinical phase I/II-study in primary liver cancer today received the initial dose of the therapeutic cancer vaccine INTUVAX®. The Company is also finalizing a clinical phase I/II-study in metastatic r (...)

Read more

The Regional Ethical Review Board approves start of Immunicum's planned liver cancer vaccine study

Gothenburg, 2013-08-21 09:12 CEST (GLOBE NEWSWIRE) -- On July 22, Immunicum AB (publ) announced that the Medical Products Agency approved the Company's application for starting a second clinical trial in primary liver cancer. Today, Immunicum announces that the Company also has received authori (...)

Read more

Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August

Gothenburg, 2013-08-19 10:05 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the last scheduled patient in the Company's phase I/II study in metastatic renal cancer has received the concluding dose of the cancer vaccine INTUVAX®.

The study is conducted at the University Hospit (...)

Read more

Company name trade mark registered in the EU

Gothenburg, 2013-08-12 15:12 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) received a trade mark registration for its Company name in the EU by OHIM (Office for Harmonization in the Internal Market).

Immunicums patented vaccine is based on over 30 years of research in the field of transplantatio (...)

Read more

The Medical Products Agency clears unique Swedish cancer vaccine for clinical tests in liver cancer patients

Gothenburg, 2013-07-22 12:38 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), which develops therapeutic cancer vaccines, has received clearance by the Swedish Medical Products Agency to start its second clinical study. The study will be conducted in 12 liver cancer patients at Sahlgrenska Univers (...)

Read more

Immunicum recruits a new Chief Operating Officer

Gothenburg, 2013-07-01 09:51 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), which develops therapeutic cancer vaccines, has appointed Henrik Elofsson as new Chief Operating Officer (COO).

As COO, Henrik Elofsson will be responsible for project management regarding preclinical and clinical trials (...)

Read more

Another trademark registered in the EU

Gothenburg, 2013-06-25 16:30 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) recently received a trade mark registration for INTUVAX® and has now also received a trade mark registration for its cancer vaccine SUBCUVAX® in the EU by OHIM (Office for Harmonization in the Internal Market).

 (...)
Read more

Trade mark registered in the EU

Gothenburg, 2013-06-20 15:02 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) has received a trade mark registration for its cancer vaccine INTUVAX® in the EU by OHIM (Office for Harmonization in the Internal Market).

Immunicums patented vaccine is based on over 30 years of research in the fie (...)

Read more

Immunicum receive extended SME-status from the European Medicines Agency

Gothenburg, 2013-06-18 10:50 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), a Swedish listed company developing therapeutic cancer vaccines, today received prolonged SME-status from the European Medicines Agency. The status is extended one year with the possibility of further extension and means (...)

Read more

Promising data for cancer vaccine INTUVAX(TM) in the treatment of kidney cancer

Press release
130520 

Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX(TM) in the treatment of metastatic renal cell carcinoma. Two patients with poor prognosis have thus far shown an average survival of abou (...)

Read more

Immunicum seeks approval for a clinical phase I/II-trial in liver cancer

Press release
130430

Immunicum AB (publ), which develops therapeutic cancer vaccines, initiated a clinical phase I/II-trial in renal cell carcinoma in February 2012. The Company has now submitted an application to the Medical Products Agency for permission to start another clinical phase I/II-trial  (...)

Read more

Immunicum conducts a private placement of 8,8 million SEK

Pressrelease
March 28, 2013

Due to the large interest in investing in Immunicum that has been shown, on March 28, 2013, the Board of Directors of the Company decided to conduct a private placement to professional investors bringing in 8,8 million SEK. This was announced in the Company's investment  (...)

Read more

Immunicum AB (publ) issues new shares before listing on NASDAQ OMX First North

Press release
4th of March 2013

Immunicum AB (publ) is a Swedish company based in Gothenburg, which develops therapeutic cancer vaccines. Immunicum has created unique patented methods to activate the body's own immune system to attack cancer cells, including metastatic cancer with the goal of improv (...)

Read more